DiaMedica Therapeutics (DMAC) Equity Average (2018 - 2026)

DiaMedica Therapeutics has reported Equity Average for 9 years, with the latest figure at $51.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 38.4% year-over-year to $51.7 million; the trailing twelve-month figure through Mar 2026 stood at $51.7 million (up 38.4% YoY), and the FY2025 full-year result was $48.4 million, up 5.51% from the prior year.
• Equity Average for Q1 2026 stood at $51.7 million, down from $53.9 million in the prior quarter.
• The five-year high for Equity Average was $57.7 million in Q3 2023, with the low at $29.4 million in Q1 2023.
• Historically, Equity Average has averaged $43.6 million across 5 years, with a median of $43.4 million in 2023.
• Annual changes were most pronounced in 2022 — Equity Average jumped 80.57% — and 2025, when it tumbled 38.73%.
• DiaMedica Therapeutics' Equity Average stood at $33.5 million in 2022, then surged by 59.46% to $53.3 million in 2023, then fell by 16.88% to $44.3 million in 2024, then increased by 21.48% to $53.9 million in 2025, then retreated by 4.07% to $51.7 million in 2026.
• The last three Equity Average figures came in at $51.7 million (Q1 2026), $53.9 million (Q4 2025), and $39.4 million (Q3 2025), per Business Quant data.